L. Serrano

Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.

J. Arribas, J. González-García, I. Pérez-Valero, 2016, Enfermedades infecciosas y microbiologia clinica.

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

J. Arribas, V. Moreno, R. Montejano, 2022, Enfermedades infecciosas y microbiologia clinica.

Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.

J. Arribas, V. Moreno, R. Montejano, 2020, Enfermedades infecciosas y microbiologia clinica.

Toward a comprehensive care of HIV patients: finding a strategy to detect depression in a Spanish HIV cohort

F. Pulido, F. Gutiérrez, A. Hernando, 2016, AIDS care.

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients

J. Arribas, V. Moreno, R. Montejano, 2022, AIDS (London, England).

The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients

C. Tural, J. Arribas, C. Quereda, 2011, AIDS.

Effect of simplification from protease inhibitors to boosted atazanavir‐based regimens in real‐life conditions

J. González-García, V. Asensi, R. Rubio, 2010, HIV medicine.

Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV.

J. Arribas, V. Moreno, L. Martín-Carbonero, 2023, Enfermedades infecciosas y microbiologia clinica.

Impact of Pre-Existing Nrti Resistance on the Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experience Patients: Real-World Data.

J. Arribas, V. Moreno, R. Montejano, 2022, AIDS (London).